15 recruiting, 14 completed, 4 unknown, 1 active not recruiting. 12 Not applicable, 9 Phase 2, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 12 | Completed 6, Recruiting 5, Unknown 1 |
| Phase 2 | 9 | Recruiting 7, Completed 2 |
| Phase 3 | 9 | Recruiting 6, Completed 2, Unknown 1 |
Follow Narcolepsy Type 1: new trials by email Literature Review of Narcolepsy Type 1 trials Research Report on Narcolepsy Type 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo - Narcolepsy Type 1 | Phase 3 | Recruiting | Alkermes, Inc. | 150 | 2026-08-13 | 2026-10-07 |
| Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1 Active Temporal Interference Stimulation, Sham Temporal Interference Stimulation - Narcolepsy Type 1 | Not applicable | Recruiting | Xijing Hospital | 24 | 2026-08-01 | 2026-08-05 |
| Decreasing Nightmares in Adults With Narcolepsy Imagery Rehearsal Therapy (IRT) - Narcolepsy, Narcolepsy Type 1 | Not applicable | Recruiting | University of Utah | 80 | 2026-07-01 | 2026-07-15 |
| A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia TAK-360, Placebo - Idiopathic Hypersomnia, Narcolepsy Type 1 | Phase 2 / Phase 3 | Recruiting | Takeda | 500 | 2026-06-11 | 2026-09-18 |
| A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) TAK-360, Placebo - Narcolepsy Type 1 | Phase 2 | Recruiting | Takeda | 92 | 2026-06-04 | 2026-06-29 |
| A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence cleminorexton, Placebo - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 / Phase 3 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 222 | 2026-05-29 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo - Narcolepsy Type 1 | Phase 3 | Recruiting | Alkermes, Inc. | 150 | 2026-04-06 | 2026-10-07 |
| Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder Thermo test pain, Pain questionnaires, No motors symptoms evaluations - REM Sleep Behavior Disorder (iRBD), Narcolepsy Type 1 | Not applicable | Recruiting | University Hospital, Toulouse | 24 | 2026-02-24 | 2026-05-01 |
| Epidemiology of Narcolepsy Type 1 and Type 2 in Spain No intervention - Narcolepsy Type 1, Narcolepsy Type 2 | Active not recruiting | Takeda | 402 | 2025-12-02 | 2026-09-01 | |
| A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia ORX750 - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 90 | 2025-08-12 | 2026-04-16 |
| Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population Blood sample, Stool sample, CSF sample - Narcolepsy Type 1, Bacterial Translocation | Recruiting | Centre Hospitalier Universitaire de Nīmes | 120 | 2025-03-10 | 2025-11-17 | |
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 / Phase 3 | Recruiting | Alkermes, Inc. | 786 | 2025-01-27 | 2026-10-09 |
| A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia ORX750, Placebo - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 248 | 2024-12-23 | 2026-04-27 |
| Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions ASRT, Questionnaires, Electrophysiological recordings - Narcolepsy Type 1, Hypersomnolence | Not applicable | Recruiting | Hospices Civils de Lyon | 180 | 2024-12-03 | 2025-01-13 |
| Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia Monitoring of eating behaviors, Monitoring of sleep/wake rhythm, Measure of nocturnal sleep parameters - Narcolepsy Type 1, Idiopathic Hypersomnia | Not applicable | Recruiting | Hospices Civils de Lyon | 76 | 2024-10-16 | 2026-06-03 |
| A Study of TAK-861 in People With Narcolepsy Type 1 TAK-861, Placebo - Narcolepsy Type 1 | Phase 3 | Completed | Takeda | 105 | 2024-10-08 | 2026-07-16 |
| A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 NLS-2, Placebo - Narcolepsy Type 1, Narcolepsy With Cataplexy | Phase 3 | Unknown | NLS Pharmaceutics | 48 | 2024-07-15 | 2024-05-21 |
| A Study of TAK-861 for the Treatment of Narcolepsy Type 1 Oveporexton, Placebo - Narcolepsy Type 1 | Phase 3 | Completed | Takeda | 168 | 2024-07-02 | 2026-08-31 |
| Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy Dreem 3S recording - Narcolepsy Type 1, Hypersomnia | Completed | Beacon Biosignals | 78 | 2024-07-01 | 2026-03-17 | |
| Mentalizating in Adults Suffering from Narcolepsy Type 1. Mentalization - Narcolepsy Type 1 | Unknown | University Hospital, Toulouse | 60 | 2024-05-17 | 2024-09-25 |
Showing 20 of 35. Sign in to see all of them.
Narcolepsy (15) · Disorders of Excessive Somnolence (11) · Idiopathic Hypersomnia (7) · Cataplexy (5) · Sleep Wake Disorders (5) · Sleep Paralysis (2) · Sleepiness (2) · Dyssomnias (1) · Fatigue (1) · Hallucinations (1) · Mental Disorders (1) · Motor Activity (1) · Narcolepsy 1 (1) · Nervous System Diseases (1) · Obesity (1)
Mental Disorders (24) · Nervous System Diseases (24) · Sleep Disorders, Intrinsic (23) · Dyssomnias (22) · Sleep Wake Disorders (20) · Disorders of Excessive Somnolence (12) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Neurologic Manifestations (7) · Parasomnias (3) · REM Sleep Parasomnias (3) · Behavior (1) · Body Weight (1) · Neurobehavioral Manifestations (1) · Nutrition Disorders (1)
Cognitive Behavioral Therapy (2) · Accelerometry (1) · Blood Specimen Collection (1) · Mentalization-Based Therapy (1) · Psychotherapy, Group (1) · Surveys and Questionnaires (1)
Takeda (8) · Alkermes, Inc. (4) · Centessa Pharmaceuticals (UK) Limited (3) · Hospices Civils de Lyon (3) · University Hospital, Toulouse (2) · Assistance Publique Hopitaux De Marseille (1) · Azienda Usl di Bologna (1) · Beacon Biosignals (1) · Boston Children's Hospital (1) · Cantonal Hospital of St. Gallen (1) · Centre Hospitalier Universitaire de Nīmes (1) · Guy's and St Thomas' NHS Foundation Trust (1) · I.M. Sechenov First Moscow State Medical University (1) · Institute of Behavioral Sleep Medicine, Colombia (1) · Liu Yonghong (1)
United States (17) · France (16) · Italy (11) · Spain (11) · Australia (8) · Japan (7) · Netherlands (6) · Belgium (5) · Canada (5) · China (5) · Switzerland (4) · Finland (3) · Germany (3) · Norway (3) · Sweden (3)
Alexander Kuts (1) · Catherine Dunyach-Remy (1) · Dagmar A Schmid, Dr. med (1) · Dennis Hwang, MD (1) · Eric Zhou, PhD (1) · George Apostol, MD, MS (1) · Jennifer Mundt, PhD (1)
PMID 42714024, PMID 10973318, PMID 11055430, PMID 28575667, PMID 31324898, PMID 32197224, PMID 36305577, PMID 37857774, PMID 40367374, PMID 40928141, PMID 41232023, PMID 41355371, PMID 41359331, PMID 42636845
2023 (2), 2025 (2)